Structure-based modulators of B1 G-protein coupled receptors
The present invention relates to a method for identifying modulators of B1 G-protein coupled receptors. The present invention also relates to a method for identifying an antagonist or agonist of the corticotropin-releasing factor receptor 2 (CRFR2). The present invention also relates to a method for improving antagonists or agonists of CRFR2. The present invention also relates to the three-dimensional structure of CRFR2 as representative of the B1 GPCR subfamily and its use as a basis for rational drug design of antagonist or agonists of B1 GPCRs.
1. A method of improving binding or activity of an agonist or antagonist of a corticotropin-releasing hormone receptor 2β extracellular domain (CRFR2β-ECD1) comprising:
a) employing the structural coordinates of mouse CRFR2β-ECD1 as set forth in Table 3 to generate a three-dimensional model in silico;
b) utilizing the model as generated in step (a) to analyze the interaction(s) of known antagonists or agonists of human CRFR2β-ECD1 to amino acids 67-69, 90-93, 102, 103 and 112-116 or combinations thereof wherein said amino acids correspond to the amino acid positions in Table 3,
d) ascertaining from step (b) where or how to modify said known antagonists or agonists so as to improve the binding or fit and modifying said agonists or antagonists thereby forming new/modified agonists or antagonists;
e) providing said new/modified agonists or antagonists; and
f) assessing the binding and/or activity of said modified/new agonists or antagonists with CRFR2β-ECD1 by contacting said new agonists or antagonists with a CRFR2β-ECD1 polypeptide.
2. The method of claim 1 , wherein the antagonist is astressin, astressin B, astressin 2 -B, urocortin I, urocortin II, or urocortin III.
3. The method of claim 1 , wherein the antagonist or agonist binds to one or more conserved amino acids in the extracellular domain of the CRFR2-ECD1.
4. The method of claim 1 , wherein the antagonist or agonist binds to a short consensus repeat domain of the extracellular domain of the CRFR2-ECD1.
5. The method of claim 1 , wherein the modified agonist or modified antagonist is a small molecule.
6. The method of claim 1 , wherein the modified antagonist or modified agonist is a peptide.
7. The method of claim 1 , wherein the modified antagonist or modified agonist is a peptidomimetic.